Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Deloitte
Harvard Business School
McKesson
Cipla
US Department of Justice

Generated: May 23, 2019

DrugPatentWatch Database Preview

Litigation Details for In re: '318 Patent Infringement Litigation (D. Del. 2005)

« Back to Dashboard

Biologic Drugs cited in In re: '318 Patent Infringement Litigation
The biologic drug covered by the patents cited in this case is ➤ Try a Free Trial .

Details for In re: '318 Patent Infringement Litigation (D. Del. 2005)

Date Filed Document No. Description Snippet Link To Document
2006-02-10 103 Letter who hold rights in United States Patent No. 5,908,850 (“the 850 patent”), against Teva, a generic drug …of a patented drug was considered patent infringement This was so even if such use of the patented drug…relevant patents. Accordingly, companies seeking to market generic drugs upon the expiration of patents that…seeks approval to market a patented product before the expiration of the patent. The purpose of this provision… that practices the 850 patent They allege that Teva infringed the 850 patent by filing an ANDA and an External link to document
2006-02-21 104 Notice to Take Deposition quot;), the owner'of U.S. Patent Nos. 6,099,863 (“the '863 patent") and 6,358,527 ("the…best of its knowledge U.S. Patent No. 6,099,863 ("the '863 patent") is invalid, unenforceable… BARR'$ ANDA Certlj?carion ihat U.S. Patent No. 6,099,863 is Invalld, Unenjbrceable, and/or Will Nor…#39;187 parent application"; now U.S. Patent No. 6,099,863), which entered National Stage in the United…ficaiion Regrrrding the '3]8 Patent _ A. The '318 Patent The ‘318 patent issued to Bonnie Davis on External link to document
2006-02-21 106 Notice to Take Deposition .S. Patent Nos. 6,099,863 (“the '863 patent") and 6,358,527 ("the '527 patent“), according… BARR'$ ANDA Cert!fica!ion that U.S. Patent No. 6,099,863 is Invalid, Unenjbrceable, and/or WIH Nar…#39;187 parent application"; now U.S. Patent No. 6,099,863), which entered National Stage in the United…ion Regarding the '318 Patent _ A. The '318 Patent The ‘31 8 patent issued to Bonnie Dayis on…catlon Regardiug the '863 Patent A. The '863 Patent The '863 patent issued to Pa\rl Marie Victor External link to document
2006-02-21 109 Notice to Take Deposition Cerrificarious for U.S. Pat. Nos. 4,663,318, 6,099,8§3 and 6,358,527 Dcar Sirs: _l°urepac Phannaceutical Co. (“Purcpae…. As used herein, “the- ‘3 1 8 patent” shall mean United States Patent No. 4,663,3 l 8. 5. As used herein… that the claims of the ‘318 patent, the ‘863 patcm, and the ‘52-7 patent are invalid and/or will not …` Ternis in a patent claim can be defined only in a way that comports With the patent as a whole. Markm…of the ‘318 patent are invalid and/or not infringed A. The ‘3 18 l’atent The ‘3 18 patent is generally External link to document
2006-02-21 111 Notice to Take Deposition "), 6,099,863 (“tlte ‘863 patent), and 6,3$3,527 (“the ‘527 patent"). Those patents were listed… the claims of the '318 patent. the ‘863 patent. and the ‘52-7 patent are invalid and/or will not …527 patents are not infringed A. The ‘863 and ‘527 Pat-sots The ‘863 patent and the ‘527 patent are … 4. As used herein, “the ‘318 patent” shall mean United States Patent No. 4,663,318. 5. As used herein… ` Terms in s patent claim can be defined only in a way that comports with the patent as a whole Morkman External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
QuintilesIMS
Federal Trade Commission
Johnson and Johnson
Boehringer Ingelheim
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.